Trevor Allred
Stock Analyst at Oppenheimer
(4.70)
# 143
Out of 5,162 analysts
19
Total ratings
83.33%
Success rate
39.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Downgrades: Perform | n/a | $13.78 | - | 2 | Mar 5, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $275 → $277 | $202.91 | +36.51% | 9 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $83 → $81 | $69.41 | +16.70% | 2 | Feb 25, 2026 | |
| LEGN Legend Biotech | Initiates: Outperform | $75 | $18.75 | +300.00% | 1 | Jan 7, 2026 | |
| DSGN Design Therapeutics | Initiates: Outperform | $18 | $10.12 | +77.87% | 1 | Jan 7, 2026 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $80 | $28.00 | +185.71% | 2 | Sep 23, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $85 | $122.06 | -30.36% | 1 | Sep 9, 2025 | |
| INVA Innoviva | Initiates: Outperform | $35 | $22.03 | +58.87% | 1 | Aug 11, 2025 |
Theravance Biopharma
Mar 5, 2026
Downgrades: Perform
Price Target: n/a
Current: $13.78
Upside: -
Ligand Pharmaceuticals
Feb 27, 2026
Maintains: Outperform
Price Target: $275 → $277
Current: $202.91
Upside: +36.51%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $83 → $81
Current: $69.41
Upside: +16.70%
Legend Biotech
Jan 7, 2026
Initiates: Outperform
Price Target: $75
Current: $18.75
Upside: +300.00%
Design Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $18
Current: $10.12
Upside: +77.87%
MBX Biosciences
Sep 23, 2025
Maintains: Outperform
Price Target: $38 → $80
Current: $28.00
Upside: +185.71%
Palvella Therapeutics
Sep 9, 2025
Initiates: Outperform
Price Target: $85
Current: $122.06
Upside: -30.36%
Innoviva
Aug 11, 2025
Initiates: Outperform
Price Target: $35
Current: $22.03
Upside: +58.87%